Motivation: The PAM50 classifier is used to assign patients to the highest correlated breast cancer subtype irrespectively of the obtained value. Nonetheless, all subtype correlations are required to build the risk of recurrence (ROR) score, currently used in therapeutic decisions. Present subtype uncertainty estimations are not accurate, seldom considered or require a population-based approach for this context. Results: Here we present a novel single-subject non-parametric uncertainty estimation based on PAM50's gene label permutations. Simulations results (n ¼ 5228) showed that only 61% subjects can be reliably 'Assigned' to the PAM50 subtype, whereas 33% should be 'Not Assigned' (NA), leaving the rest to tight 'Ambiguous' correlations between subtypes. The NA subjects exclusion from the analysis improved survival subtype curves discrimination yielding a higher proportion of low and high ROR values. Conversely, all NA subjects showed similar survival behaviour regardless of the original PAM50 assignment. We propose to incorporate our PAM50 uncertainty estimation to support therapeutic decisions. Availability and Implementation: Source code can be found in 'pbcmc' R package at Bioconductor. Contacts:
Introduction
The cancer molecular signature Prediction Analysis on Microarrays, best known as PAM50 (Parker et al., 2009; Perou et al., 2000 Perou et al., , 2010 , uses a 50 gene centroid-based Spearman's correlation model to assign individuals to one of five intrinsic molecular subtypes: basal-like (Basal), Her2-enriched (Her2), luminal A (LumA), luminal B (LumB) or normal-like (Normal). This classification has prognostic implications and has been widely used to guide patient treatment based upon the risk of recurrence (ROR) score obtained from PAM50 subtype correlations in combination with proliferation-associated genes and tumour size (ROR-PT) (Nielsen et al., 2010) . Several authors have shown that data processing steps, technology and population variability have an effect on the measured gene expression, causing subtype assignment biases (Ebbert et al., 2011; Ioannidis, 2007; Lusa et al., 2007; Paquet and Hallett, 2015; Sørlie et al., 2001 Sørlie et al., , 2010 Wu et al., 2012) .
The clinical use of PAM50 presents a series of shortcomings. First, patients are assigned using only the best correlation, even if the correlation is weak. Second, although uncertainty measurements exist, they are not taken into consideration in the usual implementations of this algorithm. Originally, the implementation by Parker et al. (2009) provided a correlation confidence measurement defined as one minus the P-value obtained while testing zero correlations with an asymptotic t-test. Third, high confidence implies that the correlation is significantly different from zero, but a weak correlation assignment can still happen with such high degree of confidence. Alternatively, Haibe-Kains et al. (2011 proposed the subtype probability as the proportion of non-negative correlations for each subtype. Controversially, weak correlations could achieve a high probability if the competitor subtype correlations are close to zero or even negative. Another shortcoming is that similar or tight subtype correlations will make no difference on the best subtype. In this sense, Cheang et al. (2009) introduced the concept of ambiguous patterns by excluding subtype correlations from the analysis for subjects with either Luminal A and B subtypes and a correlation difference between these subtypes below 0.1. Ebbert et al. (2011) estimated the PAM50 classification uncertainty by means of Monte Carlo simulations based on a priori subtype population assignment estimation. Nevertheless, all aforementioned uncertainty estimators require at least a pilot population study to normalize the subject samples, making it impractical for routine clinical use. Several authors have addressed this issue (Haibe-Kains et al., 2011 Parker et al., 2009) . Recently, Paquet and Hallett (2015) developed the Absolute Assignment of Breast Cancer Intrinsic Molecular Subtype (AIMS), which is a PAM50 alternative implementation based on a naïve Bayesian classifier of 20 gene pair comparison rules. AIMS potentially overcomes the gene normalization drawback and provides subtype posteriori probability as an uncertainty measurement. However, AIMS still assigns all subjects to the best posteriori probability, returning to the first issue of possible weak correlations.
Here, we present a novel non-parametric bioinformatics approach named Permutation-Based Confidence for Molecular Classification (PBCMC). The PBCMC implements a single-subject permutation based uncertainty estimation for PAM50 subtype assignment and does not require a previous population study to control for potential classification error. Our method was able to account for the discordance between three PAM50 implementations (Haibe-Kains et al., 2011; Paquet and Hallett, 2015; Parker et al., 2009) . In addition, we compared our results with the uncertainty measures from Parker et al. (2009 ), Haibe-Kains et al. (2011 and AIMS. The ability of assigning a true survival outcome was also assessed and compared with both the original PAM50 classification and ROR-PT scores.
Methods

Gene expression datasets
Thirty-three datasets (n ¼ 5228) previously reported in (Haibe-Kains et al., 2012) were used in our study (Table 1) . Training was conducted via implementation of the Bioconductor repository on six datasets (n ¼ 1457) (Schroeder et al., 2011a,b,c,d,e,f) . No further array-based preprocessing step was performed. For the AIMS evaluation, only the Affymetrix samples were used, offsetting the sample minimum value to have a positive expression as required by the algorithm (Paquet and Hallett, 2015) . Genes with multiple probes or features were averaged to avoid an additional source of variability in the results. Because PAM50 requires appropriate normalization of the subjects, the genes were median subtracted as suggested by Sørlie et al. (2010) . All datasets were independently processed using PAM50 implementation of genefu (Haibe-Kains et al., 2011) and ROR-PT scores as previously described (Nielsen et al., 2010) .
Permutation-Based Confidence for Molecular Classification (PBCMC)
The inspiration of PBCMC methodology is to avoid population requirement to estimate assignment uncertainty using the only available data, which is the observed subject 50 gene expression profile. Since winner correlations can be weak, we want to assess whether there is or not biological association between the subject and any PAM50 subtype. Given the non-paired nature of the data, neither the assumptions of the conventional zero association test nor its asymptotic t-test approximation hold. Thus, a better approximation to the null distribution of no association shall be to implement a permutation test based on gene label permutations of the observed subject profile as depicted by the three main blocks of PBCMC presented in Figure 1 . First, the gene expression block begins by gathering the subject's PAM50 profile (Fig. 1A) , which is gene-label permuted, thereby creating 'B' synthetic expression profiles (Fig.  1B) . Second, the PAM50 evaluation block collects both the subject and the B permuted profiles (Fig. 1A , B) to evaluate Spearman's correlation against the five PAM50's subtype centroids of Figure 1C . The resulting subject correlations are depicted as vertical lines for each subtype (Fig. 1D) , while the permuted counterparts give rise to random density histograms (Fig. 1E) . Finally, the uncertainty assessment block combines the correlation information of panels D and E. As we are looking for strong association evidence, the upper-tailed P-value is obtained for the observed sample correlation (Fig. 1D ) from the empirical null distribution for each of the five subtypes to test if there is significantly association (Fig. 1F ). These are composite hypothesis thus the P-value have to be controlled in some way. For that we use the False Discovery Rate (FDR) procedure by Benjamini and Hochberg (1995) . The classification rule gives the following outcomes: (i) 'Not Assigned' to any PAM50 subtype if all five adjusted P-values are greater than a significance threshold (a) (Fig.  1G) ; (ii) 'Assigned' to the only PAM50 subtype whose P-value is lower than a (LumA, vertical red line in (Fig. 1H ) or (iii) There are at least two informative subject correlations (red and green vertical lines (Fig. 1I ) that can lead to two different scenarios according to the difference between the top two correlations. If the correlation difference is greater than a threshold (corDif), the subject is assigned to the highest one (i.e. LumA). If this difference is below corDif, we are in the presence of an 'Ambiguous' (Amb) subject; i.e. the subject is assigned to both LumA and Normal.
Statistical analysis
All statistical analyses were performed using R version 3.2.2. Uppertailed tests were used to assess whether the observed correlations belonged to their random null simulated distributions by discrete Pvalue estimations and were corrected using the 'p.adjust' function with FDR. Parker et al. correlation confidence was computed using the 'cor.test' function with the Spearman's method option. Nonparametric Wilcoxon rank sum tests with continuity correction were used to detect statistically significant differences between two distributions using 'wilcox.test'. Contingency tables were evaluated with 'chisq.test' for independence. Mantel-Haenszel survival one-sided tests were applied (survdiff, Therneau and Grambsch, 2000) using distant metastasis-free survival endpoint. All statistical tests, except where noted, were two-sided with a P < 0.05 for statistical significance.
Results
Parameter selection for PBCMC
The PBCMC requires the values of three parameters: The number of permutations (B), uncertainty significance (a) and correlation difference cutoff (corDif). For the latter, we extended the recommendation given by Cheang et al. (2009) to use a 0.1 difference between any top subtype correlations. Several simulations with the training datasets were performed to decide which combination should be used for the other two parameters (a and B). We evaluated 1000, 10 000 and 100 000 permutations and a FDR cut-off of 0.1 down to 0.00001 to determine the number of subjects stratified into the A, NA or Amb classes (Fig. 2) . As the FDR became more stringent, the number of A subjects declined with a simultaneous increase in Amb, while the NA group remained stable. It is worth noting that the use of a FDR ¼ 0.01 resulted in a minimum number of NA subjects for all numbers of permutation tested except 1000, where the plot reached a plateau for an FDR 0:001 lower limit bounded by the inverse of the number of simulations used. Thus, the 1000 permutation option was eliminated because it failed to properly represent the null permuted density. No significant difference (Pearson v 2 test P ¼ 0.95) was found at FDR ¼ 0.01 between 10 000 and 100 000 permutations and the permutation groups (A, Amb and NA). Hence, B ¼ 10 000 permutations are recommended because of its lower computational cost, a ¼ 0:01 and corDif ¼ 0.1 for the PBCMC.
Robustness assessment
We evaluated how our strategy performed at four levels: (1) Consistency of uncertainty assignment among datasets, (2) Relationship between percentage of NA subjects and global PAM50 correlation in each dataset, (3) Comparison of the subtype assignment rendered by PBCMC with other PAM50 implementations and (4) Relationship between subtypes and permutation results. All data and results can be found in Supplementary Table S1 .
First, the global uncertainty proportion (A, Amb and NA) over the complete test and training datasets was inspected (Fig. 3A) . No significant difference among datasets was found Pearson v 2 test P ¼ 0.81). Using all datasets, subjects were stratified into A (61.17%), Amb (6.15%) and NA (32.68%) groups. A closer look into the uncertainty percentage ( Fig. 3B and Supplementary Fig. S1 ) clustered the datasets into two major groups: one group (C 1 ) associated to a high percentage of A for commercial platforms and another group (C 2 ) associated with a high percentage of NA for nonstandard platforms, except for DUKE, KOO and LUND datasets where the first two are from Affymetrix and the last from Swegene (Table 1) . Second, we took the worst (MUG), median (MAQC2) and best (DFHCC3) datasets in terms of the percentage of A to evaluate how the PAM50 subject correlation box plot behaved (Fig.  3C ). We noted that most MUG subject correlations were lower than 0.5 regardless of the permutation results (A, Amb or NA). In contrast, most A subjects of both MAQC2 and DFHCC3 had a correlation higher than 0.5, which in turn indicates more reliability to the subtype assignment in terms of biological significance. Third, we compared the PAM50 assignment obtained by genefu with the median-scale normalization (hereafter raw), Haibe-Kains et al. genefu robust normalization (hereafter Haibe-Kains) and AIMS methodology grouped according to the PBCMC uncertainty classes ( Fig.  3D and Supplementary Table S2) . A 76.82% consensus was obtained for the assignment of A subjects; the consensus was 42.83% for NA and 32.59% for Amb. Fourth, the complete dataset contingency table that depicts the PAM50 subtypes and the number of A, Amb or NA subjects is presented in Figure 3E . The most robust subtypes, in terms of the A/NA ratio, are Basal (5.03) and LumA (2.42), whereas the Normal, LumB and Her2 subtypes are classified as A or NA in almost the same proportion (0:81 < A=NA < 1:42). An expanded contingency table of ambiguous PBCMC subjects is The subject permuted counterparts are random density histograms for each subtype. (F) The correlation information of panels D and E is combined resulting into three possible outcomes: (G) In this case, the subject's correlation belongs to the random density for all subtypes, hence, the PAM50's subtype should not be used and the subject labeled as 'Not Assigned'; (H) In this example, only Luminal A (LumA) subject's correlation does not belong to the random distribution, thus, the subject should be 'Assigned' to PAM50's LumA subtype; (I) There are at least two informative subject's correlations, which can either derive into two cases according to the difference between the top two correlations. If the vertical line difference (space between arrows) is equal to or higher than a certain predefined threshold, the subject should be 'Assigned' to LumA. If it is lower than the threshold, we are in the presence of an 'Ambiguous' subject, and its corresponding PAM50's subtype assignment should be both LumA and Normal (Color version of this figure is available at Bioinformatics online.) presented in Figure 3F . The LumA-Normal subtypes were more often mixed, followed by the Her2-LumB and Basal-Normal. Interestingly, Normal is the category usually considered as the least informative because it is related to low tumour content in the original biopsy (Parker et al., 2009) , while the LumB and Her2 patients have in general a similar prognosis in terms of outcome (Creighton, 2012) . To further explore the possible advantages of our uncertainty assessment, we selected three illustrative subjects representing the PAM50 median best correlations (GSM277691, GSM102580 and GSM53078 for A, Amb and NA subjects, respectively) from the commonly used EXPO dataset (Haibe-Kains et al., 2011 Paquet and Hallett, 2015 ) (see Supplementary Table S3 ). The observed five correlations for each EXPO subject are presented in Figure 4A . Most correlations fall below 0.5 or were even negative, i. e. the subject expression profiles do not correlate with any PAM50 subtypes. Correlations above 0.5 include the Normal and Basal assignment for the Amb subject and the only true (i.e. assigned) subtype to LumB. To clarify the relevance of the assignment among the different methods, the best correlation values of EXPO subjects overlapped with the corresponding complete dataset box plots of Spearman winner correlation, Haibe-Kains et al. subtype probability, Parker et al. correlation confidence and AIMS Paquet and Hallett posteriori probability (Fig. 4B-E, respectively) . As expected, the NA group showed correlations lower than 0.5, differing significantly from both the A and Amb distributions (P < 0.001), whereas the Amb correlations, while only slightly lower than the A group, were practically overlapping (Fig. 4B) . When analysing Haibe-Kains et al. subtype probability for EXPO subjects (Fig. 4C) , a high value for the A subject was obtained, while for the Amb and NA categories, due to similar non-zero correlations, a probability almost equal to a random chance was observed. Interestingly, outlier NA subjects, with almost zero correlation (Fig. 4B) , had the top subject probability in Figure 4C , as they reached the highest proportion provided that the rest of the subtype correlations were negative. Moreover, both A and Amb subjects showed the highest Parker et al. confidence (Fig. 4D) , implying no discrimination between these two categories; together, they showed a significant difference with respect to the heavy tailed NA group (P < 0.001). Finally, AIMS (Paquet and Hallett) posteriori probability (Fig. 4E) correctly detected the GSM277691 and GSM102580 subjects (P ¼ 1) but failed to account for the GSM53078 subject where the subtype assignment was carried out using a posteriori probability almost close to a random chance (P ¼ 0.55). In fact, the overall posteriori NA probability distribution had an expected value of 1, failing in properly discriminating equivalently poor winner PAM50 correlations. Moreover, the assignment comparison among the raw genefu, Haibe-Kains and AIMS PAM50 implementations showed that these two last implementations even change the subtype assignment (Supplementary Table S2 ), particularly for the NA subjects, in which some subjects labelled as LumB are classified as LumA. This is one of the worst possible results in clinical terms, given that the LumA subjects would be treated with hormonal therapy alone, whereas the LumB subjects would benefit from additional adjuvant chemotherapy. Similarly, some Her2 subjects may be misclassified as other subtypes, whereas they should probably be candidates for targeted therapy (e.g. trastuzumab).
Impact of assigned versus not assigned categories in survival analysis
We compared the raw genefu survival curves over all training datasets for each PAM50 subtype under three different scenarios: (i) All subjects, (ii) Only A and (iii) Only NA subjects. Figure 5A showed typical survival curves for raw PAM50-classified subjects, in which LumA has the best prognosis, followed closely by Normal subjects, and Basal/Her2 subjects have poor outcomes. LumB subjects, usually considered as a group with intermediate prognosis (Goldhirsch et al., 2013) , follow the expected behaviour for just the first five follow-up years and then follow a steeper survival curve that resembles the most aggressive Basal behaviour.
When excluding from the analysis the controversial assignments (both Amb and NA), an improvement in the discriminatory power of each class outcome is achieved, particularly for the LumA and LumB subjects ( Fig. 5B and Supplementary Fig. S2 ). Both LumA and LumB assignments show significantly different survival curves for A versus NA individuals (P ¼ 0.02 and P < 0.001, respectively; Supplementary Fig. S2 ). In summary, the LumA subjects within A panel showed a better survival profile than those of the raw panel, and the assigned LumB subjects performed equally or worse than raw Basal subjects since the beginning of the follow-up period. On the contrary, the survival curves for the NA panel showed an intermediate behaviour and were not significantly different, regardless of the assigned PAM50 subtype (P ¼ 0.48), suggesting that this group may have a different prognostic behaviour than that defined by its own (non-reliable) subtype assignment (Fig. 5A, not assigned panel) .
Finally, the ROR-PT score was calculated according to their raw PAM50 assignment, and the subjects were divided into the A and NA groups (Fig. 6 ). We observed, as expected, that the A subjects (middle panel) have a significantly lower number of intermediate risk individuals (P ¼ 0.007). However, the NA group (right panel) bears a high proportion of intermediate risk subjects. The classification into intermediate risk is the least desired, as it is riskier to take therapeutic decisions when the molecular information is not strongly informative. Ambiguous subjects ( Supplementary Fig. S3 ) belong to a risk category that is usually shared by both of the assigned subtypes. This may indicate that the assignment to one or the other subtype is irrelevant in terms of ROR-PT estimation. The worst scenario is that of LumB-LumA individuals (only 9 out of 199 total subjects), in which a misclassification could lead to under treatment (Elloumi et al., 2011) . However, the ROR-PT calculation assigns them to the intermediate or high risk group, indicating that these patients could still be treated properly.
Discussion
The PBCMC has been shown to robustly fulfil the uncertainty assessment estimation identifying three complementary categories (A, Amb and NA), using only subject gene expression permutations. Our approach to a priori controls for the assignment error (FDR cut-off) and ambiguity issue (minimum acceptable correlation difference) is to define which subjects could be reliably subtyped. We propose that only the A individuals are reliable in terms of the correlation signal (confidence 1), achieving high or low ROR-PT scores. Survival discrimination is also significantly improved for the LumA and LumB subtypes according to the PBCMC. Hence, the molecular evidence is strong enough to treat A patients accordingly.
Previous works have already addressed the existence of Amb patterns, particularly regarding the LumB classification (Cheang et al., 2009; Elloumi et al., 2011) . The PBCMC extends the existence of Amb patterns to any subtypes. The fact that the expression signature of each pattern is strong enough in terms of correlation (i.e. not random) may be supported by a higher degree of tumour heterogeneity, including a higher content of normal tissue in those cases in which one of the assigned subtypes is Normal. Nevertheless, the most mixed subtypes have similar prognosis in terms of outcome when tested by ROR-PT, suggesting that the best PAM50 subtype is useful in terms of value for guiding therapy.
The previous PAM50 classification error ( < 10%) was characterized by Ebbert et al. relying on Monte Carlo simulations, using an a priori population subtype assignment, which could already have been biased. Consequently, they reported the conditional subtype error, instead of the global population classification error as intended (Molinaro et al., 2005) . Conversely, our strategy does not rely on a priori assignment and allows single subject prediction.
It may be argued that the molecular subtyping of 30% of NA subjects, even when unreliable from a statistical point of view, may not necessarily imply a lack of biological information. In this sense, we must clarify that the NA subjects were consistently classified as only one molecular subtype, even with a poor correlation, in agreement with previous studies that address the reproducibility of the PAM50 classification (Nielsen et al., 2014) . However, when analysing the survival behaviour of NA subjects, it is evident that the association of the assigned subtype with its outcome is not statistically significant. In fact, the NA subjects behave as a homogeneous group in terms of survival (better than Basal-Her2 but worse than LumANormal). Further analysis should be carried out to characterize this group. However, patients labelled as NA should not be treated according to their PAM50 subtype but according to other clinical and pathological evidence.
A potential limitation of our results is that the comparison between the AIMS and PBCMC subtypes was only performed with data of the Affymetrix platform (Haibe-Kains et al., 2012) , excluding relative expression datasets because the independent channels were not available. It is also important to mention that the method is presented here with an implementation for PAM50, but can easily be extended to other correlation-based molecular signature algorithms.
Conclusion
In summary, we recommend the use of PBCMC analysis prior to reporting the PAM50 subtype and/or ROR-PT score to assign proper weight to the biological information collected and to take into account its limitations in determining therapeutic options, in agreement with a previous report (Elloumi et al., 2011) . In this context, we propose that only A and Amb individuals are reliable in terms of their ROR-PT score and that those patients labelled as NA should not be treated according to their PAM50 subtype but only according to other clinical and pathological evidence.
